MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on December 17, 2007; DOI: 10.1124/mol.107.044289

0026-895X/08/7303-613-615$20.00
Mol Pharmacol 73:613-615, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.107.044289v1
73/3/613    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Vore, M.
Right arrow Articles by Leggas, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vore, M.
Right arrow Articles by Leggas, M.
Perspective

Progesterone Acts via Progesterone Receptors A and B to Regulate Breast Cancer Resistance Protein Expression

Mary Vore, and Markos Leggas

Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky

The breast cancer resistance protein (BCRP; ABCG2) is an ATP-dependent efflux multidrug transporter that belongs to the G family of half-transporters that consist of six transmembrane-spanning domains and must homodimerize to form the active membrane transporter. It is expressed in the apical plasma membrane domain of the small intestine, endothelium, and liver, where it has been shown to play an important role in limiting drug absorption and distribution and in enhancing drug clearance, respectively. BCRP is also expressed in the apical membrane of mammary alveolar epithelia, where it mediates efflux of substrates into milk, and in the placental syncytiotro-phoblasts, where it reduces fetal exposure to these substrates. BCRP substrates include numerous drugs (topotecan, nitrofurantoin, cimetidine) as well as food carcinogens (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and the vitamins riboflavin and folic acid. BCRP expression is regulated by a number of nuclear transcription factors, including the peroxisome proliferator-activated receptor-{gamma} and Hif-1. This issue of Molecular Pharmacology includes a study (p. 845) now conclusively demonstrating that progesterone acts via the progesterone A and B receptors to regulate BCRP expression in a placental cell line.

Received December 11, 2007; accepted December 17, 2007

Address correspondence to: Dr. Mary Vore, Graduate Center for Toxicology, University of Kentucky, 1095 VA Dr, 306 HSRB, Lexington, KY 40536-0305. E-mail: maryv{at}uky.edu


Related articles in MolPharm:

Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells
Honggang Wang, Eun-Woo Lee, Lin Zhou, Peter C. K. Leung, Douglas D. Ross, Jashvant D. Unadkat, and Qingcheng Mao
MolPharm 2008 73: 845-854. [Abstract] [Full Text]  





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics